Literature DB >> 21076464

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.

Sunil Badve1, David J Dabbs, Stuart J Schnitt, Frederick L Baehner, Thomas Decker, Vincenzo Eusebi, Stephen B Fox, Shu Ichihara, Jocelyne Jacquemier, Sunil R Lakhani, José Palacios, Emad A Rakha, Andrea L Richardson, Fernando C Schmitt, Puay-Hoon Tan, Gary M Tse, Britta Weigelt, Ian O Ellis, Jorge S Reis-Filho.   

Abstract

Breast cancer is a heterogeneous disease encompassing a variety of entities with distinct morphological features and clinical behaviors. Although morphology is often associated with the pattern of molecular aberrations in breast cancers, it is also clear that tumors of the same histological type show remarkably different clinical behavior. This is particularly true for 'basal-like cancer', which is an entity defined using gene expression analysis. The purpose of this article was to review the current state of knowledge of basal-like breast cancers, to discuss the relationship between basal-like and triple-negative breast cancers, and to clarify practical implications of these diagnoses for pathologists and oncologists.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21076464     DOI: 10.1038/modpathol.2010.200

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  237 in total

1.  How do I treat "triple-negative" disease.

Authors:  Christos Vaklavas; Andres Forero-Torres
Journal:  Curr Treat Options Oncol       Date:  2011-12

2.  Myosin II isoform switching mediates invasiveness after TGF-β-induced epithelial-mesenchymal transition.

Authors:  Jordan R Beach; George S Hussey; Tyler E Miller; Arindam Chaudhury; Purvi Patel; James Monslow; Qiao Zheng; Ruth A Keri; Ofer Reizes; Anne R Bresnick; Philip H Howe; Thomas T Egelhoff
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

Review 3.  Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer.

Authors:  Nikolas Balanis; Cathleen R Carlin
Journal:  Mol Cell Endocrinol       Date:  2017-01-12       Impact factor: 4.102

4.  Immunohistochemical profile and morphology in triple - negative breast cancers.

Authors:  Chandrika Rao; Jayaprakash Shetty; Kishan Hl Prasad
Journal:  J Clin Diagn Res       Date:  2013-05-28

5.  Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers.

Authors:  Cheng-Chieh Yang; Adam LaBaff; Yongkun Wei; Lei Nie; Weiya Xia; Longfei Huo; Hirohito Yamaguchi; Yi-Hsin Hsu; Jennifer L Hsu; Dongping Liu; Jingyu Lang; Yi Du; Huang-Chun Lien; Long-Yuan Li; Rong Deng; Li-Chuan Chan; Jun Yao; Celina G Kleer; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

6.  Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.

Authors:  Sylvia S Gayle; Jennifer M Sahni; Bryan M Webb; Kristen L Weber-Bonk; Melyssa S Shively; Raffaella Spina; Eli E Bar; Mathew K Summers; Ruth A Keri
Journal:  J Biol Chem       Date:  2018-11-27       Impact factor: 5.157

7.  Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.

Authors:  Katarzyna A Ludwik; J Preston Campbell; Mingzong Li; Yu Li; Zachary M Sandusky; Lejla Pasic; Miranda E Sowder; David R Brenin; Jennifer A Pietenpol; George A O'Doherty; Deborah A Lannigan
Journal:  Mol Cancer Ther       Date:  2016-08-15       Impact factor: 6.261

8.  Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors:  Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

9.  Therapeutic potential of histamine H₄ receptor agonists in triple-negative human breast cancer experimental model.

Authors:  Diego J Martinel Lamas; Maximo Croci; Eliana Carabajal; Ernesto J V Crescenti; Lorena Sambuco; Noelia A Massari; Rosa M Bergoc; Elena S Rivera; Vanina A Medina
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

10.  MYC Is a Crucial Mediator of TGFβ-Induced Invasion in Basal Breast Cancer.

Authors:  Magdalena A Cichon; Megan E Moruzzi; Tiziana A Shqau; Erin Miller; Christine Mehner; Stephen P Ethier; John A Copland; Evette S Radisky; Derek C Radisky
Journal:  Cancer Res       Date:  2016-04-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.